2. Massey L.K., Roman-Smith H., Sutton R.A. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. J Am Diet Assoc 1993;93:901–906.

3. Ntuhaus T.J., Belzer T., Blau N., Hoppe B., Sidhu H., Leumann E. Urinary oxalate excretion in urolithiasis and nephrocalcinosis. Arch Dis Child. 2000;82:322–326.

4. Zlatopol’sky E. The physiology and pathophysiology of calcium, magnesium and phosphorus metabolism: translation from English. (pod redaktsiey S/ Klara). М.: Medicina, 1987, p. 217–278. Кгыышфт (Златопольски Э.Патофизиология обмена кальция, магния и фосфора. Почки и гомеостаз в норме и патологии: пер с англ. (под редакцией С. Клара). М.: Медицина, 1987. С. 217–278).

5. Marangella M., Fruttero B., Bruno M., Linari F. Hyperoxaluria in idiopathic calcium stone disease: further evidence of intestinal hyperabsorption of oxalate. Clin Sri. 1982;63:381–385.

6. Bushinsky D.A., Bashir M.A., Riordon D.R., Nakagawa Y., Coe F.L., Grynpas M.D.Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats. Kidney Int. 1999;55:602–612.

7. Shiri R., Koskimaki J., Hakkinen J. Tampere Ageing Male Urological Study. Effects of age, comorbidity and lifestyle factors on erectile function: Tampere Ageing Male Urological Study (TAMUS). Eur. Urol. 2004;45:628–633.

8. DeMaria E.J. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176–2183.

9. Apolikhin O.I., Sivkov A.V., Konstantinova O.V., Selykova E.P., Zatevalov A.M.,Ruchkina I.N., Getsaev T.K. A comparative assessment of volatile fatty acids contain in colon in patients with urinary stone disease and patients with urolithiasis and concomitant irritable bowel syndrome. Tezisy dokl. VIII Vserossiiskaa nauchno-prakticheskaya konferenciya s megdunarodny uchastiem “Rational pharmacotherapy in urology». February 13-14th 2014, p. 14–15. Russian (Аполихин О.И., Сивков А.В., Константинова О.В.,Селькова Е.П., Затевалов А.М., Ручкина И.Н., Гецаев Т.К. Сравнительная оценка содержания летучих жирных кислот в толстой кишке у пациентов с мочекаменной болезнью и больных уролитиазом с сопутствующим синдромом раздраженного кишечника. Тезисы докл. VIII Всероссийская научно-практическая конференция с международным участием «Рациональная фармакотерапия в урологии». 13–14 февраля 2014. С. 14–15).

10. Nelson W.K., Houghton S.G., Milliner D.S., Lieske J.C., Sarr M.G. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005;1:481–485.

11. Asplin J.R., Coe F.L. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007;177:565–569.

12. Jääskeläinen T., Ilconen S.T., Lundgvist, Erkkola at al. The positive impact of general vitamin D food fortification policy on vitamin D status in a representative adult Finish population: evidence from an 11-y follow-up based on standardized 25-hydroxyvitamin D data. Am.J Clin Nutr. 2017;105(6):1512–1520. Doi: 10.3945/ajcn.116.151415.

13. Allison M.J., Dawson K.A., Mayberry W.R., Foss J.G. Oxalobacter formigenes gen.nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol. 1985;141:1–7.

14. Kwak С. et al. Urinary Oxalate level and the Enteric Bacterium Oxalobacter formingenes in Patients with Calcium Oxalate Urolithiasis. Eur. Urol. 2003;44:475–481.

15. Sidhu H.L., Enatska L., Ogden S., Williams W.N., Allison M.J., Peck A.B. Evaluating children in the Ukraine for colonization with the intestinal bacterium Oxalobacter formingenes, using a polymerase chain reacton detection system. Mol Diagn. 1997;2:89–97.

16. Miller A.W., Dearing D. The metabolic and ecological interactions of oxalate-degrading bacteria in the mammalian gut. Pathogens. 2013;2:636–652. Doi: 10.3390/pathogens2040636.

17. Azcarate-Peril M.A., Bruno-Barcena J.M., Hassan H.M., Klaenhammer T.R.Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from lactobacillus acidophilus. Appl Environ Microbiol. 2006;72:1891–1899. Doi: 10.1128/AEM.72.3.1891-1899.2006.

18. Arvans D., Jung Y.C., Antonopoulos D., Koval J., Granja I., Bashir M., Karrar E.,Roy-Chowdhury J., Musch M., Asplin J. et al. Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. J Am Soc Nephrol. 2017;28:876–887. Doi: 10.1681/ASN.2016020132.

19. Lange J.N., Wood K.D., Wong H., Otto R., Muffarrij P.W., Knight J., Akpinar H.,Holmes R.P., Assimos D.G. Sensitivity of human strains of Oxalobacter formingenes to commonly prescribed antibiotics. Urol. 2012;79(6):1286–1289.

20. Jiang J., Knight J., Neiberg R., Holmes R.P., Assimos D.G. Impact of dietary calcium and oxalate , and oxalobacter formigenes colonization on urinary oxalate excretion. J Urol. 2011;186(1):135–139.

21. Borsatti A. Calcium oxalate nephrolithiasis: defective oxalate transport. Kidney Int 1991;39:1283–1298.

22. Mehta M., Goldfarb D.S., Nazzal L. The role of the microbiome in kidney stone formation. Int J Surg. 2016;36 (PtD):607–612. Doi: 10.1016/j.ijsu.2016.11.024.

23. Konstantinova O.V., Yanenko E.K., Perepanova T.S., Golovanov S.A., Stepanchuk Yu.Yu. The metabolism of stone-forming substances in patients with urolithiasis during administration of eubiotic containing lactobacillus with oxalate-degrading capacity. Tezisy dokl. V Vserossiiskaa konferenciya po farmakologii pochek I vodno-solevogo obmena. Cheboksary, 1997. Russian (Константинова О.В., Яненко Э.К., Перепанова Т.С., Голованов С.А., Степанчук Ю.Ю. состояние обмена камнеобразующих веществ у больных уролитиазом при применении эубиотика на основе оксалатдеградирующих лактобацилл. Тезисы докл. V Всероссийская конференция по фармакологии почек и водно-солевого обмена. Чебоксары, 1997).

24. Miller A.W., Dale C., Dearingb M.D. The Induction of Oxalate Metabolism In Vivo Is More Effective with Functional Microbial Communities than with Functional Microbial Species.

25. Menghan Liu, Hyunwook Koh, Zachary D. Kurtz, Thomas Battaglia, Amanda PeBenito, Huilin Li, Lama Nazzal. Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project Microbiome. 2017;5:108. Doi: 10.1186/s40168-017-0316-0 PMCID: PMC5571629.

26. Journal “Himiya I jizn’”. 1994;1. Russian (Журнал Химия и жизнь. 1994;1).

27. Pytel’ Yu.A., Zolotarev I.I. Uric acid urolithiasis. 1995. p. 23–24. Russian (Пытель Ю.А. Золотарев И.И. Уратный нефролитиаз. 1995. C. 23–24).

28. Emmerson B.T., Gordon R.B., Johnson L.A. Urate Kinetics in Hypoxanthine – guanine Phosphoribosyltransferase Deficiency: Their Significance for the Understanding of Gout. Quart. J. Med. 1976;45:49–61.

29. Sundy J.S., Becker M.A., Baraf H.S. et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment – failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58:2882–2891.

30. Chen C.J., Shi Y., Hearn A. et al. My D88-dependent Il-1 receptors signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 2006;116:2262–2271.

31. Horl W.H. Uremic toxins: new aspects. J Nephrol. 2000;13(Suppl 3):S83–S88.

32. Dadon M., Frochot V. Crystalluria. Clinical chemistry and laboratory medicine 2015;53(suppl 2):s1479–1487.

33. Sakhaee K. et al. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int. 1983;24(3):348–352.

34. Pak C.Y., et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003;61(3):523–572.

35. Ekaratanawong S., et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci. 2004;94(3):297–304.

36. Lieske J.C. et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis. 2006;48(6):897–904.

37. Abate N. et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386–392.

38. Maalouf N.M., et al. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5(7):1277–1281.

39. Johnson C.D., Mole D.R., Pestridge A. Postprandial alkaline tide: does it exist? Digestion 1995;56(100–106):54.

40. Вilobrov V.M., Chugaj A.V., Bessarabov V.I. Urine pH variation dynamics inhealthy individuals and calculus formers. Urol Int 1990;45:326–331.

41. Allen L., Oddoye A, Margen S. Protein-inducedhypercalciuria: a longer term study. Rev Urol.2009;11(3):134–144.

42. Grases F., March J.G., Prieto R.M., Simonet B.M., Costa-Bauzá A., García-Raja A., Conte A. Urinary phytate in calcium oxalate stone formers and healthy people-dietary effects on phytate excretion. Scand J Urol Nephrol 2000;34:162–164.

43. Gray R.W., Wilz D.R., Caldas A.E., Lemann J. The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: Studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1977;45:299–306.

44. Caldas A.E., Gray R.W., Lemann J. The simultaneous measurement of vitamin D metabolites in plasma: Studies in healthy adults and in patients with calcium nephrolithiasis. J. Lab. Clin. Med. 1978;91:840–849.

45. Tang J., Chonchol M.B. Vitamin D and kidney stone disease. Curr Opin Nephrol Hypertens. 2013;22(4):383–89. Doi: 10.1097/MNH.0b013e328360bbcd.

46. Haghighi A., Samimagham H., Gohardehi G. Calcium and vitamin D supplementation and risk of kidney stone formation in postmenopausal women. Iran J Kidney Dis. 2013;7(3):210–213.

47. Domrongkitchaiporn S., Ongphiphadhanakul B., Stitchantrakul W., Piaseu N., Chansirikam S., Puavilai G., Rajatanavin R. Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women. Osteoporos Int. 2000;11(6):486–492.

48. Nguyen S., Baggerly L., French C., Heaney R.P., Gorham E.D., Garland C.F. 25-Hydroxyvitamin D in the range of 20 to 100 ng/mL and incidence of kidney stones. Am J Public Health. 2014;104(9):1783–87. Doi: 10.2105/AJPH.2013.301368.

49. Henglong Hu, Jiaqiao Zhang, Yuchao Lu, Zongbiao Zhang, Baolong Qin, Hongbin Gao, Yufeng Wang, Jianning Zhu, Qing Wang, Yunpeng Zhu, Yang Xun and Shaogang Wang. Association between Circulating Vitamin D Level and Urolithiasis: A Systematic Review and Meta-Analysis. Nutrients. 2017;9:301. Doi:10.3390/nu9030301.

50. Iida K., Shinki T., Yamaguchi A., DeLuca H.F., Kurokawa K., Suda T. A possible role of vitamin D receptors in regulating vitamin D activation in the kidney. Proc NatlAcad Sci U S A. 1995;92(13):6112–6116.

51. Konstantinova O.V. The prediction and principles of the prevention of urinary stone recurrence. Diss. d-ra med. nauk., М., 1999. P. 39. Russian (Константинова О.В. Прогнозирование и принципы профилактики мочекаменной болезни. Автореф. дисс. д.м.н., М., 1999. С. 39).